Amicus Therapeutics shares are trading higher after the company announced it entered into a license agreement with Teva and resolved its Galafold patent litigation.
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics shares rose following a license agreement with Teva and the resolution of Galafold patent litigation.

October 17, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics' stock is trading higher due to a new license agreement with Teva and the resolution of Galafold patent litigation.
The resolution of patent litigation removes legal uncertainty, and the license agreement with Teva could lead to new revenue streams, both of which are positive for Amicus Therapeutics' stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100